Enanta Pharmaceuticals

Traded on the St. Petersburg Stock Exchange
Enanta Pharmaceuticals is a biotechnology company developing small molecule drugs for the treatment of viral infections and liver diseases.
Enanta Pharmaceuticals stock price chart
vol.
change
P/E
Net profit
P/B
Book value
P/FCF
FCF
Yield
Growth potential

Enanta Pharmaceuticals balance sheet

Report period2018 2019 2020 2021 2022 Q3 23
End date of the reporting period
Capitalization, $
Capitalization, $
Enterprise Value
Book Value
Shareholders Book Value
Current liabilities
Noncurrent liabilities
Total liabilities
Debt
Cash and cash equivalents
Net debt
Assets
Total ordinary shares
Ordinary share price

Enanta Pharmaceuticals cash flows

Report period2018 2019 2020 2021 2022 Q3 23 TTM
End date of the reporting period
Sales
Gross profit
Operation Income
Earnings
Shareholders earnings
EBITDA
Operation Cashflow
Capital expenditure
Free Cash Flow
EPS

Enanta Pharmaceuticals multipliers

Report period2018 2019 2020 2021 2022 Q3 23 TTM
P/E
E/P
P/B
P/S
P/FCF
L/A
Debt-To-Equity
Net Debt/EBITDA
EV/EBITDA

Enanta Pharmaceuticals profitability

Report period2018 2019 2020 2021 2022 Q3 23 TTM
ROA
ROE
ROS
Gross margin
EBITDA Margin
Operating margin
Enanta Pharmaceuticals assets
Enanta Pharmaceuticals cash flows

Enanta Pharmaceuticals shares

TickerNameTypeNominal valueISINPrice
ENTA:USEnanta Pharmaceuticals, Inc.Common share-US29251M1062$14.59
Enanta Pharmaceuticals news
10.05.2022
Enanta Pharmaceuticals' GAAP loss for 6 months of fiscal year 2022 was $63.707 million, up 2.1 times from $30.373 million in the previous year. Revenue decreased 10.6% to $46.364 million from $51.875 million a year earlier.
Source: {source} pictogram ir.enanta.com
Pictogram next
29.03.2022
FDA has enrolled Enanta Pharmaceuticals' drug EDP-235 into the Fast Track program. The drug is designed to treat COVID-19 and is taken once daily. EDP-235 is currently in Phase 1 trials.
Source: {source} pictogram ir.enanta.com
Pictogram next
09.02.2022
The loss of Enanta Pharmaceuticals under GAAP for the 3 months of fiscal year 2022 was $30.115 million, increasing 3.6 times compared to $8.328 million in the previous year. Revenue decreased 12.9% to $27.648 million from $31.743 million a year earlier.
Source: {source} pictogram enanta.com
Pictogram next
23.11.2021
Enanta Pharmaceuticals' GAAP loss for fiscal year 2021 was $78.996 million, up 2.2 times from $36.168 million in the previous year. Revenue decreased 20.7% to $97.074 million from $122.473 million a year earlier.
Source: {source} pictogram enanta.com
Pictogram next
All Enanta Pharmaceuticals news
General information
Company nameEnanta Pharmaceuticals
SectorHealth Care / Pharmaceuticals, Biotechnology & Life Sciences / Biotechnology / Biotechnology
Business address500 ARSENAL STREET WATERTOWN MA 02472 617 607 0800
Mailing address500 ARSENAL STREET WATERTOWN MA 02472
Websitewww.enanta.com
Information disclosurewww.sec.gov